English 
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
Description
Mitochondrial epilepsy (MIT-E) is caused due to mitochondrial dysfunction in patients with mitochondrial diseases (MD) and it is the common manifestation in MD patients. Most epilepsies caused by a mitochondrial disorder begin in childhood and usually in the first 2 years of life. However, seizures can begin within days of birth, or into adolescence or, rarely, into adult life.
Mitochondrial diseases are a heterogeneous group of diseases resulting from energy deficiency and reduced production of adenosine triphosphate (ATP) due to reduced oxidative phosphorylation. Epilepsy is one of the most common manifestations of diseases resulting from mitochondrial dysfunction, especially in children. However, the onset of seizures in MD patients can occur at any age. In some mitochondrial diseases, seizures are part of a syndrome, for example, in Alpers-Huttenlocher syndrome (AHS) and other phenotypes associated with a pathogenic variant in the POLG gene, pyruvate dehydrogenase complex (PDHc) deficiency, myoclonic red fiber epilepsy (MERRF), MELAS, or the syndrome by Leigh.
Till date, more than 300 mutations have been reported, that are known to cause a spectrum of mitochondrial diseases. Failure to produce an adequate amount of ATP or energy is considered the main reason for most of the mitochondrial pathologies, which result in multisystemic disorders. The clinical presentations are extremely severe in high energy demanding tissues, such as skeletal muscle, central nervous system, and heart muscles; however, mitochondrial dysfunction might affect any organ of the body, Additionally, there are changes in mitochondrial DNA/mtDNA(especially with the variants m.3243A> G and m.8344A> G) and in nuclear DNA/nDNA (for example, mutations in POLG) that predispose to the development of epilepsy. Furthermore, seizures are more common in complex I and/or IV of mitochondrial respiratory chain failure than in complex II and III. However, the exact phenotypic manifestation is difficult to predict.
Mitochondrial Epilepsy – Prevalence (Epidemiology)
The criteria used to diagnose mitochondrial epilepsy (MIT-E) are those of the diagnostic guidelines provided by Newcastle Mitochondrial Disease (updated January 2013). According to these criteria and the KOL perspective, the diagnosis of epilepsy within mitochondrial disorders requires the combination of clinical evaluation, MRI, and electroencephalogram (EEG). However, diagnosing mitochondrial epilepsy disorders is challenging and mostly recognized in drug-resistant seizures with other non-seizure symptoms. Diagnostic challenges such as genetic testing and biochemistry analyzer, which are expensive and time-consuming, are still a major concern for KOL and think that effective diagnostic tests and guidelines are needed that can steer the patient and healthcare professionals towards the identification of these conditions.
Prevalent cases of mitochondrial epilepsy (MIT-E) in the G7 countries are expected to increase to ~83,000 cases in 2032 with a CAGR of 0.5% for the study period (2018-2032). The United States was estimated to have the highest prevalence of mitochondrial epilepsy (MIT-E) cases in 2032, among G7 countries.
Mitochondrial Epilepsy – Current Market Size & Forecast Trends
Antiepileptic drugs are the mainstay of MIT-E treatment. The goal of epilepsy treatment is to reduce the frequency and intensity of seizures without causing treatment-related side effects or adverse outcomes. Current management of mitochondrial epilepsy relies on antiepileptic drugs (AEDs) with a market share of 100% in 2021 and is expected to decrease by 30% once new drugs will enter the disease space.
Usually, AEDs are effective in controlling seizures in nearly 70% of patients. But there is almost 30% of the population who usually do not respond to anything. This is a refractory group and falls into an unmet need. Mortality rates are highest in intensive care units, where patients often face multiple symptoms along with epilepsy and often experience coma or brain injury due to epilepsy. Emerging therapies should broaden the current disease landscape.
The market for mitochondrial epilepsy (MIT-E) therapy is projected to experience high growth during our study period, rising to ~$ 3.6 billion in 2032, with a compound annual growth (CAGR) of 0.2%. The main drivers of this growth will be the launch of the new drugs, namely Vatiquinone (therapeutic PTC), KH176 / Sonlicromanol (Khondrion), ABI-009 / Nab-sirolimus (Adi Biosciences), CY-6463 (Cyclerion Therapeutics) and Triheptanoin(Ultragenyx Pharmaceutical Inc).
Report Highlights
- Mitochondrial Disorders Epilepsy -Current Market Trends
- Mitochondrial Disorders Epilepsy -Current & Forecasted Cases across the G7 Countries
- Mitochondrial Disorders Epilepsy -Market Opportunities and Sales Potential for Agents
- Mitochondrial Disorders Epilepsy -Patient-based Market Forecast to 2032
- Mitochondrial Disorders Epilepsy -Untapped Business Opportunities
- Mitochondrial Disorders Epilepsy -Product Positioning Vis-a-vis Competitors’ Products
- Mitochondrial Disorders Epilepsy -KOLs Insight
Additional information
| Price | Single User License, 2-3 User License, Site License, Enterprise License |
|---|
Table of Contents
- Executive Summary
- Key Findings
- Mitochondrial Epilepsy (MIT-E) Disease Background
- Mitochondrial Epilepsy (MIT-E) Definition
- Symptoms & Causes
- Pathophysiology
- Genetic Basis of Mitochondrial Epilepsy
- Frequent Mitochondrial Diseases with Epilepsy
- Diagnosis & Diagnostic Recommendations
- Epidemiology and Patient Populations
- Key Findings
- Methods and data Sources
- Country Specific Diagnosed Prevalent Populations (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Mitochondrial Epilepsy Cases by Mitochondrial Disorders
- Country Specific Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Key Sources for Mitochondrial Epilepsy (MIT-E) Epidemiology and Model Parameters
- United States
- United States Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- United States Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- United States Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Germany
- Germany Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Germany Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Germany Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- France
- France Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- France Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- France Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Italy
- Italy Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Italy Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Italy Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- United States
-
-
- Spain
- Spain Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Spain Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Spain Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- United Kingdom
- United Kingdom Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- United Kingdom Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- United Kingdom Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Japan
- Japan Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Japan Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Japan Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Spain
-
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- Pharmacological Approach
- Non-Pharmacological Approach
- Unmet Needs & Mitochoindrial Associations
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Mitochondrial Epilepsy (MIT-E)
- Product Analysis
- Vatiquinone (PTC Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Triheptanoin (Ultragenyx Pharmaceutical Inc)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- ABI-009 (Abraxis Bioscience/Aadi Bioscience)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Sonlicromanol (Khondrion)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Vatiquinone (PTC Therapeutics)
- Product Analysis
-
-
-
- CY-6463 (Cyclerion Therapeutics)
- Product Profile
- Clinical Development
- KL1333 (Abliva (NeuroVive Pharmaceutical))
- Product Profile
- Clinical Development
- CY-6463 (Cyclerion Therapeutics)
-
-
- Mitochondrial Epilepsy (MIT-E)- Pricing & Reimbursement
- Future Treatment Paradigm
- Mitochondrial Epilepsy (MIT-E) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
- Sales of Drugs to Treat Mitochondrial Epilepsy (MIT-E) in the Major Pharmaceutical Markets, 2018-2032
- Patient Share of Mitochondrial Epilepsy (MIT-E) Therapies and by Drug
- Market Forecast by Country
- United States
- United States Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- United States Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- Germany
- Germany Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- Germany Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- France
- France Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- France Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- Italy
- Italy Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- Italy Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- Spain
- Spain Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- Spain Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- United Kingdom
- United Kingdom Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- United Kingdom Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- Japan
- Japan Market for Mitochondrial Epilepsy (MIT-E) 2022-2032(USD Million)
- Japan Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2022-2032(USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Mitochondrial Epilepsy (MIT-E)?
- What Factors Are Constraining the Market for Mitochondrial Epilepsy (MIT-E)?
Sample Enquiry
Related products
-
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2022, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2032 owing to changes in population demographics and increasing awareness related to this rare disease.Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2032. -
Metastatic Ovarian Cancer (mOC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Metastatic Ovarian Cancer (mOC) market is relatively large with highest market share holding drugs in 2022 i.e., Olaparib and Niraparib. By 2032, the market is expected to change due to the loss of patents of the current therapies and the uptake and launch of new therapies. In a mOC treatment setting, the Olaparib will consistently perform and will grasp the highest market share followed by other emerging drugs. The sales of the emerging therapies for the treatment of mOC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5.3 billion by 2032.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.